BioCardia, Inc. (BCDA)Healthcare | Biotechnology | Sunnyvale, United States | NasdaqCM
1.25 USD
+1.25
(0.000%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:37 a.m. EDT
Biotech distress: BCDA faces a Nasdaq notice for equity deficiency despite insider buying, trapping it below its 50-day average with negative fundamentals and no dividend safety. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.085682 |
| AutoETS | 0.087581 |
| AutoTheta | 0.087790 |
| AutoARIMA | 0.093450 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 100% |
| H-stat | 0.88 |
| Ljung-Box p | 0.071 |
| Jarque-Bera p | 0.800 |
| Excess Kurtosis | 0.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 58.994 |
| Market Cap | 13,675,465 |
| Forward P/E | -2.23 |
| Beta | 0.55 |
| Website | https://www.biocardia.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.28977275 |
| Address1 | 320 Soquel Way |
| All Time High | 78,468.75 |
| All Time Low | 1.0 |
| Ask | 1.53 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 73,410 |
| Average Daily Volume3 Month | 67,065 |
| Average Volume | 67,065 |
| Average Volume10Days | 73,410 |
| Beta | 0.547 |
| Bid | 0.9072 |
| Bid Size | 2 |
| Book Value | 0.083 |
| City | Sunnyvale |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.25 |
| Current Ratio | 1.123 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.28 |
| Day Low | 1.185 |
| Debt To Equity | 58.994 |
| Display Name | BioCardia |
| Dividend Date | 1,559,779,200 |
| Earnings Call Timestamp End | 1,743,453,000 |
| Earnings Call Timestamp Start | 1,743,453,000 |
| Earnings Timestamp End | 1,755,259,200 |
| Earnings Timestamp Start | 1,754,909,940 |
| Ebitda | -8,254,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.418 |
| Enterprise Value | 11,707,465 |
| Eps Current Year | -0.71 |
| Eps Forward | -0.56 |
| Eps Trailing Twelve Months | -1.23 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 631 3731 |
| Fifty Day Average | 1.2096 |
| Fifty Day Average Change | 0.04040003 |
| Fifty Day Average Change Percent | 0.033399496 |
| Fifty Two Week Change Percent | -28.977276 |
| Fifty Two Week High | 3.2 |
| Fifty Two Week High Change | -1.95 |
| Fifty Two Week High Change Percent | -0.609375 |
| Fifty Two Week Low | 1.0 |
| Fifty Two Week Low Change | 0.25 |
| Fifty Two Week Low Change Percent | 0.25 |
| Fifty Two Week Range | 1.0 - 3.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 847,895,400,000 |
| Float Shares | 8,344,112 |
| Forward Eps | -0.56 |
| Forward P E | -2.232143 |
| Free Cashflow | -4,657,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -4,962,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.31062 |
| Held Percent Institutions | 0.06887 |
| Implied Shares Outstanding | 10,940,372 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://quotes.nasdaq-amex.com/Quote.dll?page=multi&mode=stock&symbol=NAMC |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,717,027,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California. |
| Long Name | BioCardia, Inc. |
| Market | us_market |
| Market Cap | 13,675,465 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_9776743 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -8,228,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,675,465 |
| Number Of Analyst Opinions | 2 |
| Open | 1.2 |
| Operating Cashflow | -7,436,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 226 0120 |
| Pre Market Change | -0.00999999 |
| Pre Market Change Percent | -0.79999924 |
| Pre Market Price | 1.24 |
| Pre Market Time | 1,776,759,744 |
| Previous Close | 0.0 |
| Price Eps Current Year | -1.7605635 |
| Price Hint | 4 |
| Price To Book | 15.060242 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.035 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.25 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 1.28 |
| Regular Market Day Low | 1.185 |
| Regular Market Day Range | 1.185 - 1.28 |
| Regular Market Open | 1.2 |
| Regular Market Previous Close | 0.0 |
| Regular Market Price | 1.25 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 192,257 |
| Return On Assets | -1.44984 |
| Return On Equity | -9.50115 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 10,940,372 |
| Shares Percent Shares Out | 0.0162 |
| Shares Short | 177,342 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 218,108 |
| Short Name | BioCardia, Inc. |
| Short Percent Of Float | 0.0195 |
| Short Ratio | 3.08 |
| Source Interval | 15 |
| State | CA |
| Symbol | BCDA |
| Target High Price | 25.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 15.5 |
| Target Median Price | 15.5 |
| Total Cash | 2,496,000 |
| Total Cash Per Share | 0.228 |
| Total Debt | 528,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -1.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.4982 |
| Two Hundred Day Average Change | -0.24820006 |
| Two Hundred Day Average Change Percent | -0.16566549 |
| Type Disp | Equity |
| Volume | 192,257 |
| Website | https://www.biocardia.com |
| Zip | 94,085 |